regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-07. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In materials science and molecular biology, thermostability is the ability of a substance to resist irreversible change in its chemical or physical structure, often by resisting decomposition or polymerization, at a high relative temperature. Thermostable materials may be used industrially as fire retardants. A thermostable plastic, an uncommon and unconventional term, is likely to refer to a thermosetting plastic that cannot be reshaped when heated, than to a thermoplastic that can be remelted and recast. Thermostability is also a property of some proteins. To be a thermostable protein means to be resistant to changes in protein structure due to applied heat.
== H == Hammock – The hammock was invented by indigenous peoples of the Caribbean and Central America. The word derives from the Taíno word hamaca. Christopher Columbus observed their use in the Bahamas in 1492. Harpoons – the Inuit had developed the harpoon independent of any Old World influences, in order to hunt seals, walrus, and whales. The Inuit of West Greenland called the harpoon maupok. Harpoons enabled the Inuit to hunt large marine mammals from a distance in the umiak and kayak in the open Arctic Ocean. Hockey – both field hockey and ice hockey are based on a game called shinny. This indigenous stickball game was played throughout North America well before the European arrival.
== Action mechanism, pharmacokinetics == Like other local anesthetics belonging in the amide group trimecaine decreases the cell membrane permeability, causes depolarization and shortens the action potential. Anesthetic effect starts within 15 minutes and remains 60–90 minutes. Its biological half-life is ca. 90 minutes. 10% of trimecaine is excreted unchanged (90% as its metabolites). It passes through the hematoencephalic and placental barriers.
Sources: en.wikipedia.org
=== Other types === Various types are distinguished by the domain of life to which they belong. Physical well-being concerns the domain of the body, including the capacity to engage in physical activity and the absence of illness and bodily pain. It includes general health considerations and the ability to perform one's social role without being hindered by physical limitations. Psychological well-being, also called mental health, is a state of mind characterized by internal balance. It involves the absence or successful management of disorders and disturbances, together with the abilities to cope with challenging situations, maintain positive relationships, and cultivate personal growth. It is closely linked to intellectual, spiritual, and emotional well-being. Intellectual well-being encompasses well-functioning cognitive abilities and traits, such as critical thinking, problem-solving, and curiosity. Spiritual well-being is a state in which people find purpose in life and have inner peace, self-confidence, and a sense of identity. Emotional well-being involves the capacities to comprehend, articulate, and regulate emotions, together with an overall positive mood. Hedonic well-being refers to a life rich in pleasurable experiences and devoid of suffering. Eudaimonic well-being is a form of personal fulfillment in which an individual flourishes by striving for excellence and actualizing their innate potential.
=== GGQ catalytic site === The catalytic site that is responsible for the hydrolysis of the peptidyl tRNA is the GGQ site on eRF1. Current understanding of the GGQ site states that it enters the P-site of the ribosome, which is where the peptidyl tRNA is located, after a conformational change caused by the hydrolysis of GTP by eRF3. Furthermore, any mutation to the GGQ site renders eRF1 nonfunctional, thus the cells ability to successfully terminate Translation. This is due to the two glycine residues in GGQ to adopt a torsional angle that is only possible with two glycines. Without the proper angle, the active site for the reaction won't be able to function properly. In order nascent protein to be released the GGQ site needs to recruit a water molecule into the active site of the reaction. The method of recruitment for a single water molecule is still not understood completely. Once in position, the water molecule acts as a nucleophile, and attacks the carbonyl group of the ester bond between the nascent protein and the tRNA. The hydrolysis of the ester bond causes the release of the nascent protein and the disassembly of the ribosome and termination complex.
=== Illustrative example === The following describes the operation of a simple mass spectrometer that uses sector type. Other types are treated below. Consider a sample of sodium chloride (table salt). In the ion source, the sample is vaporized (turned into gas) and ionized (transformed into electrically charged particles) into sodium (Na+) and chloride (Cl−) ions. Sodium atoms and ions are monoisotopic, with a mass of about 23 daltons (symbol: Da or older symbol: u). Chloride atoms and ions come in two stable isotopes with masses of approximately 35 u (at a natural abundance of about 75 percent) and approximately 37 u (at a natural abundance of about 25 percent). The analyzer part of the spectrometer contains electric and magnetic fields, which exert forces on ions traveling through these fields. The speed of a charged particle may be increased or decreased while passing through the electric field, and its direction may be altered by the magnetic field. The magnitude of the deflection of the moving ion's trajectory depends on its mass-to-charge ratio. Lighter ions are deflected by the magnetic force to a greater degree than heavier ions (based on Newton's second law of motion, F = ma). The streams of magnetically sorted ions pass from the analyzer to the detector, which records the relative abundance of each ion type. This information is used to determine the chemical element composition of the original sample (i.e. that both sodium and chlorine are present in the sample) and the isotopic composition of its constituents (the ratio of 35Cl to 37Cl).
He even sent letters to the ruler of Multan, the Byzantine emperors Constantine VII and Michael IV the Paphlagonian, Jewish communities and Christian Church leaders, as well as the leader of the Qarmatians of Bahrayn, either admonishing them for having abandoned the true faith, or exhorting them to repent and convert before the imminent end times.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.